SCHEMBL27552

SCHEMBL27552

COC(=O)CCc1ccccc1C(=O)OC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.76
LMNA P02545 2/20 0.76
HSD17B10 Q99714 2/20 0.51
POLB P06746 2/20 0.51
TSHR P16473 2/20 0.50
CFTR P13569 1/20 0.49
HIF1A Q16665 1/20 0.48
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 4/20 0.47
ATM Q13315 1/20 0.47
GLA P06280 1/20 0.45
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10411824 0.90 ALDH1A1 (0.67) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL8412585 0.88 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL10499238 0.87 LMNA (0.63) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL10360804 0.87 ALDH1A1 (0.77) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL4243105 0.86 ALDH1A1 (0.57) ALDH1A1LMNAHSD17B10TSHRHIF1A
SCHEMBL8877393 0.86 ALDH1A1 (1.00) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL2439695 0.86 ALDH1A1 (0.76) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL29056995 0.86 ALDH1A1 (0.66) ALDH1A1LMNAHSD17B10POLBTSHR
SCHEMBL10438855 0.85 CYP4F2 (0.58) ALDH1A1LMNAHSD17B10TSHRKMT2A
SCHEMBL9030516 0.85 ALDH1A1 (0.73) ALDH1A1LMNAHSD17B10POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104854141-B Catalyst components for the polymerization of olefins 巴塞尔聚烯烃意大利有限公司 2020-03-10 CN disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
EP-2859026-B1 CATALYST COMPONENTS FOR THE POLYMERIZATION OF BUTENE-1 BASELL POLIOLEFINE ITALIA SRL (IT) 2017-06-28 EP disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
EP-2859024-B1 CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE SRL (IT) 2016-04-27 EP disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed
WO-2010105179-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-09-16 WO disclosed
WO-2010057865-A1 N- INDEN- 2 -YL- ISOPROPYLSULFONAMIDES AS AMPA RECEPTOR POTENTIATORS GLAXO GROUP LIMITED (GB) 2010-05-27 WO disclosed
WO-2010057865-A1 N- INDEN- 2 -YL- ISOPROPYLSULFONAMIDES AS AMPA RECEPTOR POTENTIATORS GLAXO GROUP LIMITED (GB) 2010-05-27 WO disclosed
EP-0542554-B1 Substituted N-biphenylyl lactams ORTHO PHARMA CORP (US) 1996-01-31 EP disclosed
US-5246940-A Angoitensin II receptor antagonist for hypertension, stroke or diabetes ORTHO PHARMACEUTICAL CORPORATION (US) 1993-09-21 US disclosed
EP-0542554-A1 Substituted N-biphenylyl lactams ORTHO PHARMACEUTICAL CORPORATION (US) 1993-05-19 EP disclosed
US-5182288-A Angiotensin II receptor antagonists ORTHO PHARMACEUTICAL CORPORATION (US) 1993-01-26 US disclosed
EP-0002624-B1 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1981-10-14 EP disclosed
EP-0002624-A1 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1979-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 ALDH1A1 2962/4885LMNA 521/4885HSD17B10 834/4885
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 ALDH1A1 2962/4885LMNA 521/4885HSD17B10 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.